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Background: The antineoplastic role of peroxisome proliferator-activated receptor gamma (PPARγ) ligandshas previously been 
demonstrated in several gastric cancer cell lines. Activation of PPARγ by polyunsaturated fatty acids (PUFAs) inhibits growth and 
proliferationof tumor cells. In this double-blind clinical study, we evaluate the effect of PUFAs on PPARγ mRNA expression in pa-
tients with gastric adenocarcinoma. Materials and Methods: A total of 34 chemotherapy-naive patients diagnosed with gastric 
adenocarcinoma were enrolled in the present study. According to treatment strategies, all subjects were divided into two groups, 
the first group (17 individuals) received cisplatin without supplements and the second group (17 individuals) received cisplatin plus 
orally administered PUFAs supplements for 3 weeks. The gastric biopsy samples were obtained from all participants before and 
after treatment, and PPARγ mRNA expression levels were evaluated by quantitative real-time polymerase chain reaction using 
validated reference genes. Results: Our findings revealed that PPARγ mRNA expression is significantly upregulated in group II af-
terreceiving cisplatin plus orally administered PUFAs supplements for three weeks (p < 0.0001), whereas PPARγ mRNA expres-
sion did not show significant alteration in group I after receiving cisplatin alone. Conclusion: The results of the study evidence that 
PPARγ may act as a potential target for the therapy of human gastric adenocarcinoma.
Key Words: peroxisome proliferator-activated receptor gamma, PPARγ, PUFAs, gastric cancer.
Gastric cancer is the fourth most common cancer 
among both men and women in the world [1, 2]. Ac-
cording to Cancer Facts and Figures, by the American 
Cancer Society, in 2015, 24,590 estimated new cases 
of gastric cancer will be diagnosed, and 10,720 deaths 
will occur in the United State [3]. Although, the in-
cidence and mortality rate of gastric cancer have 
decreased dramatically in many nations, it still ranks 
2nd as the leading cause of cancer related deaths glob-
ally [4]. In Iran with about 8000 deaths annually, gastric 
cancer remains the first cause of cancer related death 
in both sexes [5]. It is evidenced that gastric cancer 
is a complicated and multifactorial disease, which 
is caused by inherited and acquired risk factors [2, 6]. 
The best known risk factors for gastric cancer include 
Helicobacter pylori infection, chronic atrophic gastri-
tis, hypertrophic gastropathy, gastric polyps, obesity, 
endogenous formation of N-nitroso compounds, high 
salt intake, and malnutrition of antioxidants [2, 7]. In the 
last decades, widespread molecular studies have been 
performed to discover the detailed molecular mecha-
nisms which involved in development and progression 
of gastric cancer [8–12]. Although, these investigations 
have been unearthed more clues of the gastric cancer 
nature which may be lead us towards treatment of can-
cer and introduce anticancer drugs, the most puzzling 
facets of gastric cancer is still remained enigmatic.
Peroxisome proliferator-activated receptors 
(PPARs) belong to a subfamily of the steroid nuclear 
hormone receptor superfamily of ligand-activated 
intracellular transcription factors [13]. To date, three dif-
ferent isoforms of PPARs (PPARα, PPARβ/δ and PPARγ) 
have been identified, each with tissue specific distribu-
tion and ability to interact with diverse classes of com-
pounds [14]. PPARγ regulates the expression of myriad 
genes that modulate energy metabolism, inflammatory 
response, cell differentiation, and apoptosis [15]. When 
activated by specific ligands, PPARγ heterodimerizes 
with the retinoid X receptor (RXR) to form a complex 
(PPAR/RXR) and regulates expression of target genes 
by binding to the peroxisome proliferator response ele-
ment (PPRE) [16]. The target genes that are transcrip-
tionally activated by PPARγ regulate multiple signaling 
pathways, including those related to p21, p53, nuclear 
factor κB, BCL2, STAT, and cyclin D1 [17]. The ability 
of PPARγ to regulate the expression of genes involved 
in cell differentiation, cell cycle control and apoptosis 
allows to propose that altered expression of PPARγ may 
be associated with tumorigenesis [18]. Compounds 
that activate PPARγ comprise the heterogeneous group 
that includes polyunsaturated fatty acids (PUFAs) and 
eicosanoids, as well as synthetic activators [19]. Anti-
cancer effects of PPARγ ligands have been reported 
in several gastric cancer cell lines, an effect attribu ted 
to induction of apoptosis, cell cycle arrest and inhibi-
tion of growth and proliferation [20]. However, the role 
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of orally administered PUFAs supplements on PPARγ 
mRNA expression in gastric cancer has not been inves-
tigated in depth. Therefore, we designed a double-blind 
clinical study in patients with gastric adenocarcinoma 
to investigate the effect of PUFAs on PPARγ mRNA 
expression.
MATERIALS AND METHODS
Subjects. A total of 34 chemotherapy-naive pa-
tients with histologically and/or cytologically confirmed 
gastric adenocarcinoma were recruited from Liver 
and Gastrointestinal Diseases Research Center and 
Hematology-Oncology Research Center, Tabriz, Iran, 
during 2013–2015. The patients with diabetes, pyloric 
obstruction, cardiac obstruction, renal dysfunction and 
inflammatory diseases were excluded from the study. 
Eligible subjects were assigned to one of two groups 
in a double-blind manner. Group I (17 individuals; 
mean age, 67.5 ± 11.2 years) received cisplatin without 
supplements (50 mg/m2 intravenous per 4 weeks for 
3 months), while Group II (intervention group) (17 indi-
viduals; mean age, 71.3 ± 9.8 years) received cisplatin 
plus orally administered PUFAs supplements (Natural 
Factors Omega Factors Ultimate 1200 mg capsules, 
supplements of ω-3, ω-6, and ω-9 fatty acids with the 
formula of fish oil blend 400 mg, flax seed oil 400 mg, 
borage oil 400 mg) in the scale of 3600 mg per day for 
3 weeks. Demographic and clinical properties of two 
groups are shown in Table 1. The present study was 
approved by the Ethics and Human Rights Commit-
tee of Tabriz University of Medical Sciences, Tabriz, 
Iran, and the informed consents were filled out by all 
participants.
RNA extraction and cDNA synthesis. All gastric 
biopsy samples were stored in RNAlater solution (Qia-
gen, Germany) at −80 °C until RNA extraction. Total 
RNA was isolated from tissue samples using RNeasy 
kit (Qiagen, Valencia, CA) and RNA yield was treated 
with RNase-free DNase (MBI Fermentas, Canada), 
according to the manufacturer’s instructions. The 
quality and quantity of extracted RNA were confirmed 
by agarose gel electrophoresis and NanoDrop® ND-
1000 Spectrophotometer (Thermo Scientific, USA), re-
spectively. Subsequently, total RNA (1 μg) was reversely 
transcribed to cDNA using RevertAid™ First Strand 
cDNA Synthesis Kit (Fermentas, Canada) with random 
hexamer primer, following the manufacturer’s protocol.
Quantitative real-time polymerase chain reac-
tion (PCR). Real-time PCR was conducted in triplicate 
using gene-specific primers as shown in Table 2 and 
SYBR Green (SYBR Premix Ex Taq RT-PCR kit, Takara) 
by the Rotor-GeneTM 6000 system (Corbett Research, 
Australia) according to the manufacturer’s instructions. 
Each reaction mixture contained 100 ng cDNA, master 
mix 2X, ROX dye 50X, and 10 pmol of each primer pairs 
for PPARγ and GAPDH in a final volume of 25 μl. Initial 
denaturation at 94 °C for 5 min was followed by 50 cycles 
(for PPARγ) and 35 cycles (for GAPDH) of denaturation 
at 94 °C for 10 s, annealing at temperatures that are 
mentioned in Table 2 for each primer pairs for 15 s, 
extension at 72 °C for 20 s. Standard curves were 
plotted using serially diluted cDNA and the expres-
sion levels of PPARγ in the samples were normalized 
through the mean expression of the house keeping gene 
GAPDH. We also used no template negative control.
Table 1. Demographic and clinical properties of the subjects
Characteristic All subjects (n = 34) p valuecGroup I (n = 17)a Group II (n = 17)b
Age, years 67.5 ± 11.21 71.25 ± 9.81 0.235
Gender 0.695
Male (n = 19) 9 10
Female (n = 15) 8 7
Tumor stage 0.809
I (n = 7) 4 3
II (n = 11) 6 5
III (n = 9) 4 5
IV (n = 7) 3 4
Tumor primary location 0.714
Upper (n = 11) 5 6
Median (n = 13) 6 7
Lower (n = 10) 6 4
Tumor size 0.759
≤ 4 cm (n = 16) 7 9
> 4 cm (n = 18) 10 8
Familial history of gastric cancer 0.730
Yes (n = 19) 9 10
No (n = 15) 8 7
Smoking status 0.714
Current smoker (n = 12) 6 6
Second smoker (n = 11) 4 7
Never-smoker (n = 11) 7 4
Systolic blood pressure, mmHg 131.1 ± 9.20 128.8 ± 10.20 0.235
Diastolic blood pressure, mmHg 85.10 ± 7.10 79.20 ± 7.90 0.985
Fasting glucose, mg/dI 98.54 ± 15.25 102.85 ± 18.65 0.234
Cholesterol, mg/dI 148.98 ± 21.56 151.25 ± 25.65 0.125
Triglyceride, mg/dI 87.25 ± 18.25 78.25 ± 15.65 0.256
Note: Continuous variables were expressed as mean ± standard deviation (SD).
aGroup I; received cisplatin without supplements. bGroup II; received cispl-
atin plus orally administered PUFAs supplements (Natural Factors Omega 
Factors Ultimate 1200 mg capsules, supplements of ω-3, ω-6, and ω-9 fat-
ty acids with the formula of fish oil blend 400 mg, flax seed oil 400 mg, bor-
age oil 400 mg) in the scale of 3600 mg per day for three weeks. cEvaluat-
ed by One way ANOVA and Fisher’s χ2 tests.
Table 2. Sequence of primers used in quantitative real-time PCR, the am-
plicon sizes and the annealing temperature of each reaction
Gene Sequence of primers Amplicon size (bp)
Annealing 
temperature 
(°C)
PPARγ F5´-CTTCTCCAGCATTTCTACTCCAC-3´ 126 60
R5´-GCAGGCTCCACTTTGATTG-3´
GAPDH F5´-GAAGGTGAAGGTCGGAGTC-3´ 218 60.5
R5´-GAAGATGGTGATGGGATTTC-3´
Statistical analysis. Statistical analysis was per-
formed using SPSS software version 16.0 (SPSS Inc., 
Chicago, IL, USA). Analysis of the distribution of PPARγ 
mRNA expression levels around cutoff points using 
Kolmogorov — Smirnov test showed that the data were 
normally distributed and thus, parametric statistical 
tests were used to compare the data. We used Stu-
dent’s t-test to determine the statistically significant 
difference in the expression of PPARγ before and after 
treatment in both groups. p Values <0.05 were consi-
dered statistically significant.
RESULTS
We investigated the mRNA expression level 
of PPARγ in 34 patients diagnosed with gastric adeno-
carcinoma before and after treatment with cisplatin 
alone and cisplatin plus orally administered PUFAs 
supplements using quantitative real-time PCR me-
thod, and the ratio of the PPARγ expression analyzed 
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by the 2−ΔΔct method. Initial analysis of the distribution 
of PPARγ mRNA expression level using Kolmogorov — 
Smirnov test showed that the data were normally 
distributed (p < 0.001). Therefore, the median ratio 
of PPARγ expression level was chosen as the cut-off 
value in subsequent analysis (Table 3).
Table 3. PPARγ expression level in two groups
PPARγ mRNA expression
Before treatment After treatment
Patients Median Range Median Range p valuea
Group Ib 0.880 0.51–1.20 0.970 0.58–1.50 0.331
Group IIc 0.810 0.38–1.26 1.60 0.80–2.30 0.0001
Note: ap value calculated by Student’s t-test. bGroup I — received cisplatin 
without supplements. cGroup II — received cisplatin plus orally administered 
PUFAs supplements (Natural Factors Omega Factors Ultimate 1200 mg cap-
sules, supplements of ω-3, ω-6, and ω-9 fatty acids with the formula of fish 
oil blend 400 mg, flax seed oil 400 mg, borage oil 400 mg) in the scale 
of 3600 mg per day for three weeks.
Our results demonstrated that the mRNA expres-
sion level of PPARγ did not show significant alteration 
in patients treated with cisplatin alone, before and after 
treatment (p = 0.331) (Table 3, Figure). The median ratio 
of PPARγ expression in group I patients before and after 
treatment were 0.88 (range 0.51–1.20) and 0.97 (range 
0.58–1.50), respectively (Table 3). We found that the 
mRNA expression level of PPARγ was upregulated 
in patients treated with cisplatin plus orally administered 
PUFAs supplements (Table 3, Figure). Comparison 
of the PPARγ expression level before and after treat-
ment with cisplatin plus orally administered PUFAs 
supplements in group II using Student’s t-test indicated 
that there is statistical significant difference between 
them (p < 0.0001) (Table 3, Figure). The median ratio 
of PPARγ expression in group II patients before and after 
treatment were 0.81 (range 0.38–1.26) and 1.60 (range 
0.80–2.30), respectively (Table 3).
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Figure. Box plot graph depicting the mRNA PPARγ expression 
levels in both groups before and after treatment. Group I — re-
ceived cisplatin without supplements and Group II — received 
cisplatin plus orally administered PUFAs supplements
DISCUSSION
Owing to the critical role of PPARγ in cell cycle 
progression, cell differentiation and apoptosis, a large 
body of researches has been focused on PPARγ 
as a putative target for the prevention and treatment 
of cancer [21, 22]. However, the precise role of PPARγ 
in carcinogenesis is not very well understood. The 
antineoplastic activity of PPARγ ligands in gastric 
cancer has been reported by P.C. Konturek et al. [23]. 
Accordingly, in the present study we investigated the 
effect of PUFAs on PPARγ mRNA expression in patients 
with gastric adenocarcinoma. Our results revealed that 
PPARγ mRNA expression level is significantly upregu-
lated in patients who were treated with cisplatin plus 
orally administered PUFAs supplements (p < 0.0001). 
In line with our data, previous studies showed that ac-
tivation of the PPARγ inhibits proliferation, and in some 
cases induces apoptosis in gastric cell lines [24–27]. 
Takahashi et al. [24] has reported that troglitazone, 
as a PPARγ ligand, transactivated the transcription 
of a peroxisome proliferator response element-driven 
promoter in human gastric cancer cell line, MKN45. 
The authors concluded that PPARγ activation sup-
presses cell growth and induce apoptosis in gastric 
cancer cells [24]. The inhibitory effects of PPARγ 
agonists (troglitazone and 15-deoxy-Delta(12,14)-
prostaglandin J2) on the proliferation of the gastric 
cancer cells has been suggested by H. Sato et al. [25]. 
They proposed that induction of apoptosis together 
with G1 cell cycle arrest may be one of the mecha-
nisms of the antiproliferative effect of PPARγ activation 
in human gastric cancer cells [25]. Y.X. Chen et al. [26] 
investigated the effect of PPARγ ligand, 15-deoxy-12, 
14-prostaglandin J2 on the proliferation and apoptosis 
of MCG-803 human gastric cancer cell lines, and re-
ported that this ligand inhibits cell growth and induces 
apoptosis of MCG-803 cells. In another study, it has 
been shown that troglitazone inhibits gastric carcino-
genesis in mice through PPARγ activation [27]. In light 
of these studies and our data, it seems that PUFAs, 
as a ligand of PPARγ, could inhibit progression and 
development of gastric cancer through upregulation 
of PPARγ mRNA expression. However, C.W. Cheon 
et al. [28] proposed that troglitazone and ciglitazone 
inhibit the proliferation of SNU-216 and SNU-668 gas-
tric cancer cells through a PPARγ independent path-
way. When they used GW9662, an antagonist of PPARγ, 
in conjunction with ciglitazone and troglitazone, the 
cell growth suppression effect was unaffected [28]. 
X.M. Ma et al. [29] also reported that PPARγ agonist 
15-deoxy-Delta12,14-prostaglandin J(2) suppresses 
growth of human gastric carcinoma MGC803 cells 
by inducing apoptosis and G1/G0 cell cycle arrest with 
the involvement of survivin, Skp2 and p27 and not via 
PPARγ. Therefore, further studies may be required 
to discover the exact molecular basis of the activities 
regulated by PUFAs such as PPARγ activation on gas-
tric tumor behavior.
In conclusion, our findings showed that treatment 
based on orally administered PUFAs supplements 
leads to upregulation of PPARγ expression in patients 
with gastric adenocarcinoma. These data provide ad-
ditional evidence to support the hypothesis that PPARγ 
may act as a potential target for the therapy of human 
gastric adenocarcinoma.
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